Wall Street Zen cut shares of Quince Therapeutics (NASDAQ:QNCX – Free Report) from a hold rating to a sell rating in a research note published on Saturday morning.
Several other research analysts have also recently issued reports on the company. Craig Hallum assumed coverage on Quince Therapeutics in a research note on Thursday, August 20th. They issued a “buy” rating and a $68.00 price objective on the stock. Oppenheimer began coverage on shares of Quince Therapeutics in a research note on Wednesday, July 29th. They set an “outperform” rating and a $82.00 price objective for the company. Lifesci Capital upgraded Quince Therapeutics to a “strong-buy” rating in a research note on Monday, June 29th. Leerink Partners assumed coverage on shares of Quince Therapeutics in a report on Wednesday, June 24th. They issued an “outperform” rating and a $80.00 price target for the company. Finally, Weiss Ratings raised Quince Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Quince Therapeutics has a consensus rating of “Hold” and a consensus target price of $260.00.
Check Out Our Latest Research Report on QNCX
Quince Therapeutics Trading Down 1.3%
Quince Therapeutics (NASDAQ:QNCX – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($12.31) EPS for the quarter, beating analysts’ consensus estimates of ($28.02) by $15.71.
Hedge Funds Weigh In On Quince Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Quince Therapeutics in the second quarter valued at about $31,000. XTX Topco Ltd acquired a new stake in shares of Quince Therapeutics during the second quarter worth about $37,000. Intellectus Partners LLC acquired a new position in shares of Quince Therapeutics in the 4th quarter valued at $179,000. Bridgeway Capital Management LLC increased its stake in Quince Therapeutics by 20.9% in the second quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock valued at $212,000 after purchasing an additional 22,200 shares during the period. Finally, Hudson Bay Capital Management LP acquired a new position in Quince Therapeutics in the 4th quarter valued at about $213,000. 30.75% of the stock is currently owned by institutional investors and hedge funds.
Quince Therapeutics Company Profile
Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.
Featured Stories
- Five stocks we like better than Quince Therapeutics
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
